PBR Nachrichten

 

The collaboration involves up to $56m in upfront payments to AbCellera for the first two research programmes, with an additional $28m payable if a third programme begins within The post Jazz and AbCellera sign deal for T-cell engagers in solid tumours appeared first on Pharmaceutical Business review....

Executives from both organisations, including LG AI Research head Woohyung Lim and D&D Pharmatech CEO Seulki Lee, attended the event to formalise the partnership. The project focuses on The post LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs appeared first on Pharmaceutical Business review....

The agreement broadens AviadoBio's existing rights, which were previously limited to the development of gene therapies for neurological diseases under a 2020 agreement. The vMiX platform leverages adeno-associated The post AviadoBio broadens vMiX gene silencing licence with King's College London appeared first on Pharmaceutical Business review....

Under the deal, Simulations Plus shareholders will receive $18.50 per share, representing a 26% premium to the 60-day volume-weighted average price as of 15 June 2026. The company's The post Altaris to acquire Simulations Plus in $375m all-cash deal appeared first on Pharmaceutical Business review....

The FDA granted the status to alixorexton for idiopathic hypersomnia while the EC approved the designation for narcolepsy. In the US, the ODD offers incentives such as tax The post Alkermes' alixorexton secures FDA and EC orphan designations appeared first on Pharmaceutical Business review....

This approval is said to be the first in the UK for a needle-free adrenaline treatment for children aged four years and older, weighing between 15kg and less The post ALK's EURneffy secures MHRA approval for anaphylaxis treatment appeared first on Pharmaceutical Business review....

Under the deal, Simcere will provide funding for exploratory research on a first-in-class novel molecule in the respiratory field. If the research is successful, Simcere will have the The post Simcere and Stanford partner to develop IPF therapies appeared first on Pharmaceutical Business review....

This approval covers patients with ccRCC who are at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions. This marks the The post FDA clears MSD's Keytruda combo plus Welireg for ccRCC treatment appeared first on Pharmaceutical Business review....

The approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies. Study results showed that gumokimab delivered rapid and strong efficacy. The post China's NMPA approves Akeso's gumokimab for plaque psoriasis appeared first on Pharmaceutical Business review....

The application covers patients with stage III colon cancer characterised by deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) or microsatellite instability-high (MSI-H). The FDA is anticipated to make The post FDA grants priority review for Roche's Tecentriq combo sBLA appeared first on Pharmaceutical Business review....

The collaboration follows a successful pilot phase, where XtalPi's integrated quantum physics and AI algorithms achieved improved hit rates, highlighting the platform's capability to address the complex metabolic target. The post XtalPi enters $400m partnership for small molecule therapy for GPCR target appeared first on Pharmaceutical Business review....

EMA has now begun reviewing its use in adults following a non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack (TIA). The validation confirms the application is complete The post EMA validates Bayer's asundexian application for ischaemic stroke appeared first on Pharmaceutical Business review....

Upon completion of the transaction, Ignite will separate from Aditxt and is expected to become an independent public company via the establishment of a new holding entity, anticipated The post Aditxt and Ignite announce merger plans with strategic partner appeared first on Pharmaceutical Business review....

The programme will investigate the ways in which AI can enhance the evaluation of precision and safety, better forecast risks, and identify impacts that current methods might overlook. The post MHRA to roll out new AI sandbox for medicines development appeared first on Pharmaceutical Business review....

The deal centres on enhancing targeted treatments for solid tumours driven by KRAS mutations, which are considered especially challenging to treat. The companies stated that the Firelink DAC The post J&J to acquire Firefly Bio for $1bn to enhance oncology pipeline appeared first on Pharmaceutical Business review....

The approval covers patients aged 12 years and older with inhibitors, as well as children aged six to 11 years, with or without inhibitors. Hympavzi is approved for The post Pfizer's Hympavzi secures FDA expanded indications for haemophilia appeared first on Pharmaceutical Business review....

The decision follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Aqneursa is approved across the EU The post EC grants marketing authorisation for IntraBio's Aqneursa appeared first on Pharmaceutical Business review....

The partnership includes a five-year licence for Owkin's K Pro, an AI platform designed to augment drug discovery and development. Since 2021, Sanofi and Owkin have maintained a The post Sanofi and Owkin partner to develop next-generation biopharma AI agents appeared first on Pharmaceutical Business review....

This partnership provides the biopharmaceutical company with early access to the Chai-3 model alongside a dedicated model tailored to Pfizer's proprietary data and workflows, underscoring a strategic move The post Pfizer signs licence agreement with Chai for AI drug discovery appeared first on Pharmaceutical Business review....

This advance recognises preliminary data indicating that salanersen may show substantial improvement over existing therapies for SMA. The FDA's decision follows data from a Phase Ib study on The post Biogen's salanersen gains FDA breakthrough therapy designation for SMA appeared first on Pharmaceutical Business review....